The Science

Tap into your brain’s power to take on depression symptoms

Rejoyn was developed with the principles of harnessing the brain’s natural ability to change and adapt.

Watch the video to learn more 
about how Rejoyn works:

How exercises can change the brain

  • The brain exercises in Rejoyn involve identifying and remembering emotions on a series of faces
  • Identifying the emotions is designed to activate the feeling part of the brain
  • Remembering the emotions is designed to activate the thinking part of the brain

Activating these parts at the same time helps them work together.

Clinical Trials

In clinical trials, patients who regularly performed brain exercises showed improvements in their symptoms, which lasted after treatment had finished.3-7

The majority of patients who took part in a clinical trial using Rejoyn finished their treatment.5,8

No side effects related to Rejoyn were reported in a pivotal clinical trial.5

Interested in Rejoyn?

Rejoyn is currently only available in certain locations. To check availability in your area, click below:

Check Availability

Further Information

If you have further questions or would like to learn more about Rejoyn, you can check our FAQs or contact us below:

Contact us

References

  1. Diener C et al. Neuroimage 2012;61:677–685.
  2. Hoch MM et al. Chronic Stress (Thousand Oaks) 2019;3:2470547019877880.
  3. Iacoviello BM et al. Depress Anxiety 2014;31:699–706.
  4. Iacoviello BM et al. NPJ Digit Med 2018;1:21.
  5. Rothman B et al. Presented at the Psych Congress 2024 Annual Meeting. 29 October – 02 November 2024, Boston, MA, USA. Poster 185.
  6. Cochran J et al. Presented at the Psych Congress 2024 Annual Meeting. 29 October – 02 November 2024, Boston, MA, USA. Poster 79.
  7. Cochran J et al. Presented at the Psych Congress 2024 Annual Meeting. 29 October – 02 November 2024, Boston, MA, USA. Poster 78.
  8. Cochran J et al. Presented at the Psych Congress 2024 Annual Meeting. 29 October – 02 November 2024, Boston, MA, USA. Poster 77.

Date of preparation: June 2025 | UK-152-2500018 (v1.0)

Intended Use

Rejoyn is a digital therapeutic intended for the treatment of depressive disorder episodes in adults. It is intended to be used alongside usual care and supported by a Healthcare Professional.
Please read the Instructions For Use for Rejoyn.

Adverse Events

Adverse events should be reported. Reporting forms and information can be found at
www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. To report Rejoyn side effects or quality complaints, contact +44 (0) 808 168 6726 or OPUKSafety@otsuka.co.uk

Download on the App StoreGet It On: Google Playstore

Access code required

Please see How to Access Rejoyn for more info

Otsuka

This webpage is for the general public with an interest in Rejoyn, an app developed by Otsuka Pharmaceutical Europe Ltd.
Please note that Rejoyn requires a prescription or referral from a healthcare professional.

Date of preparation: June 2025
UK-152-2500021 (v1.0)

Necessary Cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.